<DOC>
	<DOCNO>NCT01026623</DOCNO>
	<brief_summary>This phase I/II trial study side effect give cixutumumab together temsirolimus see well work treat patient metastatic prostate cancer . Monoclonal antibody , cixutumumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Temsirolimus may stop growth tumor cell block enzymes need cell growth . Giving cixutumumab together temsirolimus may kill tumor cell .</brief_summary>
	<brief_title>Cixutumumab Temsirolimus Treating Patients With Metastatic Prostate Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To confirm safety tolerability IMC-A12 ( cixutumumab ) temsirolimus use recommend phase II dose level advance solid tumor chemo-naive patient metastatic castration-resistant prostate cancer rise prostate-specific antigen ( PSA ) . ( Phase I ) II . To confirm safety tolerability IMC-A12 temsirolimus give every three week dose schedule . ( Phase I Extension ) II . To determine tumor response rate and/or composite time progression ( cTTP ) chemotherapy-naive patient castration-resistant prostate cancer ( CRPC ) receive combination IMC-A12 CCI-779 ( temsirolimus ) . ( Phase II ) SECONDARY OBJECTIVES : I . To determine maximal percent decrease PSA baseline . II . To determine change PSA doubling time ( PSADT ) . III . To determine time PSA progression 6-month progression-free survival ( PFS ) . IV . To determine rate adverse event . EXPLORATORY OBJECTIVES : I . To evaluate change circulate tumor cell ( CTC ) number time . II . To evaluate IGF1R androgen receptor ( AR ) CTCs correlate response . III . To evaluate profile CTCs molecular level polymerase chain reaction ( PCR ) prostate cancer-specific gene . IV . To explore association clinical outcome , administration therapy , serial fludeoxyglucose F 18 ( FDG ) -positron emission tomography ( PET ) imaging . V. To correlate fluorine F 18 FMDHT ( 18-FDHT ) -PET image finding outcome measure response . VI . To perform tumor biopsy evaluate biomarkers may correlate active feedback tumor response therapy , include anti-insulin receptor substrate 1 ( IRS-1 ) , anti-IRS-2 , phosphorylated ( p ) protein kinase B ( Akt ) ( S473 ) , p-ribosomal protein S6 kinase ( 70/S6K ) , anti-phospho-AKT1 substrate 1 ( proline-rich ) ( PRAS 40 ) , phosphatase tensin homolog gene ( PTEN ) status . OUTLINE : This multicenter study . Patients receive cixutumumab intravenously ( IV ) 60-70 minute temsirolimus IV 30 minute day 1 , 8 , 15 , 22 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow 4 week .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma prostate Distant metastases evaluable radionuclide bone scan , CT scan , magnetic resonance imaging ( MRI ) within past 28 day Evidence progressive disease androgendeprivation therapy ( include trial antiandrogenwithdrawal therapy ) , define ≥ 1 follow criterion : Progressive measurable disease use conventional solid tumor criterion Bone scan progression , define ≥ 2 new lesion bone scan Increasing PSA , define ≥ 2 consecutive rise PSA value reference value take ≥ 1 week apart ( third PSA value must great second PSA value , , fourth PSA value must great second PSA value ) Castrate level serum testosterone ( i.e. , ≤ 50 ng/dL ) No know brain metastasis Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 01 OR Karnofsky PS 70100 % Life expectancy &gt; 6 month Leukocytes ≥ 3,000/μL Absolute neutrophil count ( ANC ) ≥ 1,500/μL Platelet count ≥ 100,000/μL Hemoglobin ≥ 9 g/dL Total bilirubin ≤ 2 time upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 time ULN Serum creatinine ≤ 1.5 time ULN Creatinine clearance ≥ 50 mL/min Able adhere study visit schedule study requirement Fertile patient must use effective contraception , , 3 month completion study treatment Adequate lung function ( pulmonary function test ≥ 70 % diffusion capacity lung carbon monoxide [ DLco ] ) No poorly control diabetes mellitus Patients history diabetes eligible provide blood glucose normal ( i.e. , fast blood glucose &lt; 120 mg/dL &lt; ULN ) stable dietary therapeutic regimen No malignancy within past 3 year except treat basal cell squamous cell carcinoma skin superficial transitional cell carcinoma bladder No uncontrolled major illness include , limited , follow : Active infection , include human immunodeficiency virus ( HIV ) infection viral hepatitis Symptomatic congestive heart failure ( class III IV ) Unstable angina pectoris Myocardial infarction acute coronary syndrome within past year Serious cardiac arrhythmia Significant lung disease Major psychiatric illness No concurrent anticancer agent treatments No prior chemotherapy , except neoadjuvant chemotherapy No prior antiinsulinlike growth factor receptor ( IGFR ) agent mammalian target rapamycin ( mTOR ) inhibitors No prior strontium89 , rhenium186 , rhenium188 , samarium153 radionucleotide therapy Prior standarddose radiotherapy pelvis prostate cancer and/or additional externalbeam radiotherapy metastatic site allow More 4 week since prior surgery , radiotherapy , combine androgen blockade ( exclude singleagent gonadotropin releasinghormone agonists/antagonists ) , investigational therapy No concurrent secondline hormonal agent , include ketoconazole , diethylstilbestrol , estrogenlike agent , finasteride No concurrent corticosteroids unless patient stable maintenance dose hydrocortisone ( ≤ 30 mg/day ) ≥ 3 month</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>